| Name | Title | Contact Details |
|---|
Temperature Control Solutions for Laboratory and Production from -125 °C to +425 °C
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
Impactful healthcare provided by kind people so Western New Yorkers can achieve their dreams and goals. Quality care, regardless of ability to pay. #unstoppable
Bottled Fitness is a Valparaiso, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...